Niraparib and Pembrolizumab for Advanced Triple-Negative Breast Cancer or Recurrent Ovarian Cancer
Patients with platinum-resistant ovarian cancer have few treatment options. Data from the phase 1/2 TOPACIO/Keynote-162 trial for a subset of 60 evaluable patients with recurrent ovarian cancer (64% platinum-resistant, 19% platinum-refractory, 17% platinum-sensitive) were presented at the 2018 ASCO annual meeting. Patients in the open-label study received a combination of niraparib (Zejula), an oral PARP inhibitor, and pembrolizumab (Keytruda), an anti-PD-1 immunotherapy agent. In the evaluable population, overall response rate (ORR) was 25% and disease-control rate (DCR) was 68%. Median duration of response was 9.3 months. The ORR was 25% in patients with platinum-resistant disease and 45% in patients with BRCA-mutated tumors, who had a DCR of 73%. The most common grade 3 or 4 treatment-related adverse events were anemia (19%) and thrombocytopenia (9%).
Read more here.
Reference
Konstantinopoulos PA, Waggoner SE, Vidal GA, et al. TOPACIO/Keynote-162 (NCT02657889): a phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—results from ROC cohort. Presented at: 2018 American Society of Clinical Oncology; June 1-5, 2018; Chicago, Illinois. Abstract 106.
